Claim · 2026-01-12 · announcement · Stated in source · Supported

NVIDIA's 12 January 2026 release states that Lilly announced a collaboration with NVIDIA to launch a co-innovation lab on drug discovery, describing the initiative as "representing a total investment of up to $1 billion expected in talent, infrastructure and compute over five years".

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

NVIDIA → announced a partnership with → Eli Lilly and Company

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

NVIDIAannounced a partnership with ↓Eli Lilly and Company

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2026-01-12 · announcement Records dated 2026 →
Activity stage: announced

Scope and limitsAn announced collaboration. The "up to $1 billion" is an expected total over five years as stated, not a payment, and the release does not allocate it between the companies; the release's own phrase "first-of-its-kind" is not adopted. The “up to” figure stays in the statement and is not recorded as an amount (maintainer decision of 2026-10-30).

The evidence 02

primary sourceSupports the claim

NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery

NVIDIA · 2026-01-12

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Today, Lilly announced a first-of-its-kind collaboration with NVIDIA to launch a co-innovation lab focused on tackling some of the most enduring challenges in drug discovery.”

Location in source paragraph after the platform list

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: NVIDIA
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 c1524022fb61d821667af941fb30cfea948eea5d08630dcf3f46c0d779bbf77f). NVIDIA Newsroom release dated January 12, 2026, as served on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: NVIDIA, “NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery”, 2026-01-12.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (25 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A31) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

primary sourceSupports the claim

NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery

NVIDIA · 2026-01-12

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“representing a total investment of up to $1 billion expected in talent, infrastructure and compute over five years”

Location in source section "Lilly and NVIDIA Announce Landmark Co-Innovation AI Lab"

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: NVIDIA
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 c1524022fb61d821667af941fb30cfea948eea5d08630dcf3f46c0d779bbf77f). NVIDIA Newsroom release dated January 12, 2026, as served on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: NVIDIA, “NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery”, 2026-01-12.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (18 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A31) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An organisation announced a collaboration or partnership with a named counterparty, as the announcement states it (stage announced). It is not evidence that the work was performed, that a payment was made or that the arrangement continues; an “up to” amount stays in the statement.

Date. Dated by the release.

Record ID aib-labs-nv-lilly-co-innovation-lab-2026